Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone ISM Bioavailability Study in Schizophrenia
NCT03527186Phase 1Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Jul 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Area Under the Curve Over the Dosing Interval. Started Jul 2018; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03527186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527186.